Treatment patterns and outcomes in KRAS

Advanced NSCLC Immune checkpoint inhibitors Immunotherapy KRAS(G12C) Non-small cell lung cancer Real-world data Sotorasib Systemic therapy Targeted therapy Treatment patterns

Journal

Lung cancer (Amsterdam, Netherlands)
ISSN: 1872-8332
Titre abrégé: Lung Cancer
Pays: Ireland
ID NLM: 8800805

Informations de publication

Date de publication:
25 Jul 2024
Historique:
received: 03 06 2024
revised: 18 07 2024
accepted: 20 07 2024
medline: 30 7 2024
pubmed: 30 7 2024
entrez: 29 7 2024
Statut: aheadofprint

Résumé

KRAS mutations, particularly KRAS From the CAnadian CAncers With Rare Molecular Alterations-Basket Real-world Observational Study (CARMA-BROS), a cohort of 102 patients with KRAS The patients (median age 66 years; 58 % female; 99 % current/former tobacco exposure; 59 % PD-L1 ≥ 50 %), exhibited heterogeneous treatment patterns post-ICI. Most patients received ICIs as a first-line therapy, with varying subsequent lines including chemotherapy and targeted therapy. In patients receiving systemic therapy post-ICI, median overall survival was 12.6 months, and real-world progression-free survival was 4.7 months. KRAS This study contributes valuable real-world data on KRAS

Identifiants

DOI: 10.1016/j.lungcan.2024.107898 PMID: 39074423
pubmed: 39074423
pii: S0169-5002(24)00432-X
doi: 10.1016/j.lungcan.2024.107898
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107898

Informations de copyright

Copyright © 2024 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The study was supported by Amgen. The authors have no other conflicts of interest to declare.

Auteurs

Samir H Barghout (SH)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Pharmacology & Toxicology, Faculty of Pharmacy, Tanta University, Tanta, Egypt.

Luna Jia Zhan (LJ)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Starvroula Raptis (S)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Faisal Al-Agha (F)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Niki Esfahanian (N)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Aimee Popovacki (A)

Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.

Goulnar Kasymjanova (G)

Jewish General Hospital, Montreal, QC, Canada.

Francis Proulx-Rocray (F)

Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada.

Sze Wah Samuel Chan (SWS)

Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, ON, Canada.

Matthew Richardson (M)

University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, Canada.

M Catherine Brown (MC)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Devalben Patel (D)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Michelle Liane Dean (ML)

Glans-Look Lung Cancer Research, University of Calgary, Calgary, AB, Canada.

Vishal Navani (V)

Glans-Look Lung Cancer Research, University of Calgary, Calgary, AB, Canada; Tom Baker Cancer Centre, Calgary, AB, Canada.

Erica Moore (E)

CancerCare Manitoba Research Institute, Winnipeg, MB, Canada.

Lane Carvery (L)

Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.

Elizabeth Yan (E)

Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, ON, Canada.

Daniel Goldshtein (D)

Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, ON, Canada.

Jasmine Cleary-Gosine (J)

Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.

Amanda Jw Gibson (AJ)

Glans-Look Lung Cancer Research, University of Calgary, Calgary, AB, Canada.

Lynn Hubley (L)

Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.

Karmugi Balaratnam (K)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Tran Ngo (T)

Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.

Azee Gill (A)

Brampton Civic Hospital, William Osler Health System, Brampton, ON, Canada.

Morgan Black (M)

London Health Sciences Centre, London, ON, Canada.

Adrian Sacher (A)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Penelope A Bradbury (PA)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Frances A Shepherd (FA)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Natasha Leighl (N)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Parneet Cheema (P)

Brampton Civic Hospital, William Osler Health System, Brampton, ON, Canada.

Sara Kuruvilla (S)

London Health Sciences Centre, London, ON, Canada.

Jason Agulnik (J)

Jewish General Hospital, Montreal, QC, Canada.

Shantanu Banerji (S)

CancerCare Manitoba Research Institute, Winnipeg, MB, Canada.

Rosalyn Juergens (R)

Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, ON, Canada.

Normand Blais (N)

Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada.

Winson Cheung (W)

Glans-Look Lung Cancer Research, University of Calgary, Calgary, AB, Canada; Tom Baker Cancer Centre, Calgary, AB, Canada.

Paul Wheatley-Price (P)

University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, Canada.

Geoffrey Liu (G)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. Electronic address: Geoffrey.Liu@uhn.ca.

Stephanie Snow (S)

Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada. Electronic address: stephanie.snow@nshealth.ca.

Classifications MeSH